Professor Prow has a drug delivery leadership profile that is supported (since 2016) by research income >$14.5M, 35 peer-reviewed translational research publications (>140 total), six patent families and named on 19 Human Ethics Committee approvals. Professor Prow’s clinical research focus is reflected in all 23 grants and 28/35 publications, since 2016. Professor Prow’s leadership in drug delivery is evidenced by $7.5M in translational research funding (lead investigator in 11/18 projects).
Drug Delivery. A total of $1.86M of that funding was for translational, topical drug delivery projects that underpinned his drug delivery research focus on skin cancer. He led all drug delivery (7/9) grants (including Professor... Read more
About me
Professor Prow has a drug delivery leadership profile that is supported (since 2016) by research income >$14.5M, 35 peer-reviewed translational research publications (>140 total), six patent families and named on 19 Human Ethics Committee approvals. Professor Prow’s clinical research focus is reflected in all 23 grants and 28/35 publications, since 2016. Professor Prow’s leadership in drug delivery is evidenced by $7.5M in translational research funding (lead investigator in 11/18 projects).
Drug Delivery. A total of $1.86M of that funding was for translational, topical drug delivery projects that underpinned his drug delivery research focus on skin cancer. He led all drug delivery (7/9) grants (including Professor Prow’s NHMRC Fellowship), except two that were NHMRC fellowships for his post-doctoral fellows. These high profile NHMRC fellowships are evidence of Professor Prow’s commitment to mentorship. Professor Prow is an invited member of the Advanced Drug Delivery Reviews (5-year impact factor 15.5) editorial board, supporting his role as a global thought leader in drug delivery.
Skin Cancer. Professor Prow has built a strong international profile in the skin cancer field as evidenced by 13/19 human ethics committee approved protocols involving skin cancer and precursors, 16/35 peer-reviewed publications since 2015 with a skin cancer focus and >$10M in competitive funding skin cancer research.
Commercialisation. Translation through commercialisation is Professor Prow’s vision for his research projects. Professor Prow’s key collaboration with Almirall on topical drug-induced apoptosis in skin cancer is an important step towards that outcome. Professor Prow has a successful commercialisation track record, e.g. skin microbiopsy intellectual property, 2018 USPTO granted, is being commercialised by Trajan Sci & Med, Melbourne, AUS. Professor Prow is a named inventor of topical drug delivery technology currently licensed to Vaxxas, a $55 M start-up company.
About me
Date | Title |
---|---|
01/10/2019 |
Tiny medicine, big impact | TEDxUNISA | Professor Tarl Prow , https://youtu.be/gHOwoceOPqQ |
18/04/2018 |
Detecting Skin Cancer | Enterprising Research Talks | Professor Tarl Prow , https://youtu.be/07UW5QEvXQM |
12/12/2015 |
Skin Scanner Story | Scope TV | Professor Tarl Prow , https://youtu.be/hTyQKs601rs |
21/08/2015 |
New technology to track moles | Professor Tarl Prow , https://youtu.be/rba0fsfSaQc |
08/01/2015 |
Innovative technologies to diagnose skin diseases | Professor Tarl Prow, https://youtu.be/fboofJRVmEQ |
Intellectual property:
Introduction to skin Microbiopsy: Microbiopsy video
Introduction to Foroderm: Foroderm video
Current Projects:
Topical drug delivery for aged skin and skin cancer, see Prow TW, Mandinova A.Adv Drug Deliv Rev. 2020 Jan 1;153:1. doi: 10.1016/j.addr.2020.07.009.
Skin microsampling for environmental exposure, see The toxic chemicals that leach into soil, dust, skin and lungs – and don’t break down
Minimally invasive skin cancer diagnostics, see 'Mind your Moles' study; Melanoma Evolution; and Microbiopsy Biomarker Profiling in Skin Cancer
Research
Excludes commercial-in-confidence projects.
Quantifying third hand exposure to methamphetamine in residential settings, ARC - Linkage Project, 14/04/2022 - 13/04/2025
Impact of exposure pathway and source on PFAS absorption and bioavailability, NHMRC TCR into Per- and Poly- Fluoroalkylated Substance, 01/04/2020 - 31/03/2024
Micromedial device development, NHMRC - Career Development Fellowship, 27/03/2017 - 31/12/2019
Research
Research outputs for the last seven years are shown below. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2017 |
3
|
2017 |
|
2016 |
8
1
|
2016 |
1
|
2016 |
1
|
2015 |
|
2015 |
2
1
|
2014 |
4
|
2013 |
5
|
2011 |
10
|
Year | Output |
---|---|
2021 |
Open access
3
4
2
|
2021 |
1
|
2021 |
|
2021 |
Open access
1
1
4
|
2021 |
Open access
1
1
11
|
2021 |
1
|
2021 |
Open access
2
2
|
2020 |
5
|
2020 |
|
2020 |
Open access
1
1
4
|
2020 |
Open access
11
11
2
|
2020 |
Open access
1
1
1
|
2020 |
Open access
1
1
3
|
2020 |
Open access
11
10
1
|
2019 |
Open access
37
38
4
|
2019 |
Open access
4
2
5
|
2019 |
47
44
158
|
2018 |
Open access
12
12
5
|
2018 |
Open access
75
73
97
|
2018 |
Open access
16
17
4
|
2017 |
16
17
4
|
2017 |
24
25
2
|
2017 |
Open access
23
20
17
|
2017 |
Open access
19
18
38
|
2017 |
10
8
16
|
2016 |
Open access
14
15
2
|
2016 |
Open access
8
4
|
2016 |
Open access
7
7
1
|
2016 |
1
|
2016 |
Open access
9
8
4
|
2016 |
16
14
4
|
2016 |
8
8
4
|
2015 |
8
9
|
2015 |
Open access
16
11
|
2015 |
Open access
35
33
7
|
2015 |
15
15
4
|
2015 |
10
11
|
2015 |
9
9
3
|
2015 |
10
10
2
|
2015 |
Open access
6
5
|
2015 |
Open access
11
7
15
|
2015 |
Open access
148
135
2
|
2014 |
7
6
|
2014 |
Open access
29
28
2
|
2014 |
Open access
29
26
2
|
2014 |
Open access
22
21
4
|
2014 |
Open access
49
52
|
2014 |
16
16
3
|
2014 |
Open access
43
43
|
2014 |
Open access
10
11
|
2013 |
16
16
|
2013 |
94
84
1
|
2013 |
Open access
27
12
|
2013 |
Open access
1
1
|
2013 |
22
20
|
2013 |
22
22
3
|
2013 |
21
18
|
2013 |
Open access
39
33
|
2013 |
7
8
1
|
2012 |
9
9
|
2012 |
Open access
19
19
|
2012 |
12
12
|
2012 |
82
72
|
2012 |
66
62
2
|
2012 |
13
12
1
|
2011 |
38
38
|
2011 |
88
78
|
2011 |
70
65
|
2011 |
88
74
|
2011 |
597
539
|
2011 |
130
108
|
2010 |
105
97
|
2010 |
Open access
135
126
|
2010 |
67
56
|
2010 |
56
47
|
2010 |
138
130
|
2010 |
121
108
|
2010 |
Open access
78
59
|
2010 |
Open access
52
45
|
2009 |
152
137
|
2009 |
60
52
|
2008 |
Open access
44
33
|
2008 |
Open access
24
17
|
2008 |
Open access
85
78
|
Year | Output |
---|---|
2016 |
13
2
|
2016 |
Open access
2
2
|
2016 |
Open access
4
3
|
2015 |
|
2014 |
2
|
2010 |
|
2008 |
9
1
|
2008 |
2
1
|
Research
Intellectual property:
Introduction to skin Microbiopsy: Microbiopsy video
Introduction to Foroderm: Foroderm video
Current Projects:
Topical drug delivery for aged skin and skin cancer, see Prow TW, Mandinova A.Adv Drug Deliv Rev. 2020 Jan 1;153:1. doi: 10.1016/j.addr.2020.07.009.
Skin microsampling for environmental exposure, see The toxic chemicals that leach into soil, dust, skin and lungs – and don’t break down
Minimally invasive skin cancer diagnostics, see 'Mind your Moles' study; Melanoma Evolution; and Microbiopsy Biomarker Profiling in Skin Cancer
Research
Details | Registry | Status |
---|---|---|
Prow, TW; Soyer, HP |
AU | Filed |
Prow, Tarl W; Soyer, H Peter; Ansaldo, Alex |
EP | Filed |
Prow, Tarl W; Soyer, H Peter; Ansaldo, Alex |
WO | Filed |
Prow, TW; Raphael, AP |
AU | Filed |
Chen, X; Prow, TW; Fernando, G; Kendall, MAF |
AU | Filed |
Kendall, Mark Anthony Fernance; Fernando, Germain; Chen, Xianfeng; Prow, Tarl |
US | Granted |
Method and composition for delivering a compond through a biological barrier Prow, TW |
AU | Filed |
Method and composition for delivering a compound through a biological barrier Prow, Tarl W; Soyer, H Peter |
EP | Filed |
Method and composition for delivering a compound through a biological barrier Prow, Tarl W; Soyer, H Peter |
US | Filed |
Method and composition for delivering a compound through a biological barrier Prow, Tarl W; Soyer, H Peter |
WO | Filed |
Prow, Tarl W; Soyer, H Peter; Ansaldo, Alexander Bernard |
US | Granted |
Prow, TW; Raphael, AP; Chen, X; Kendall, MAF |
AU | Filed |
External engagement & recognition
Organisation | Country |
---|---|
Addis Ababa University | ETHIOPIA |
Alexandria University | EGYPT |
Blaze Bioscience, Inc. | UNITED STATES |
Cancer Council Queensland | AUSTRALIA |
Cedars-Sinai Medical Center | UNITED STATES |
Chinese University of Hong Kong | HONG KONG |
City University of Hong Kong | HONG KONG |
CTA Pathology | UNITED STATES |
Curtin University | AUSTRALIA |
Dermatologie am Regierungsviertel | GERMANY |
Douglass Hanly Moir Pathology | AUSTRALIA |
Duke University | UNITED STATES |
Federal University of Sao Paulo | BRAZIL |
Food and Drug Administration | THAILAND |
Fred Hutchinson Cancer Research Center | UNITED STATES |
Garvan Institute of Medical Research | AUSTRALIA |
Ghent University | BELGIUM |
Griffith University | AUSTRALIA |
Hebrew University | MEXICO |
INM Institute | GERMANY |
IQ Pathology | AUSTRALIA |
IRCCS Foundation | ITALY |
IRCCS Istituto Dermopatico dell'Immacolata | ITALY |
Johns Hopkins Hospital | UNITED STATES |
Johns Hopkins University | UNITED STATES |
Karmaweb S.r.l | ITALY |
King Saud University | SAUDI ARABIA |
LEO Pharma A/S | DENMARK |
L'Oreal Paris | FRANCE |
Macquarie University | AUSTRALIA |
Massachusetts General Hospital | UNITED STATES |
Moscow State University | RUSSIAN FEDERATION |
Newcastle Skin Check | AUSTRALIA |
NEWRO Foundation | AUSTRALIA |
North Carolina State University - Raleigh | UNITED STATES |
Northwest PK Solutions | UNITED STATES |
Obj Ltd | AUSTRALIA |
Princess Alexandra Hospital | AUSTRALIA |
Princess Alexandra Hospital Brisbane | AUSTRALIA |
Private Individual | AUSTRALIA |
Public Health Virology, Queensland Health Forensic and Scientific Services | AUSTRALIA |
QIMR Berghofer Medical Research Institute | AUSTRALIA |
Queensland Health | AUSTRALIA |
Queensland Institute of Medical Research | AUSTRALIA |
Queensland University of Technology | AUSTRALIA |
Reggio Emilia | ITALY |
Saarland University | GERMANY |
San Gallicano Dermatological Institute | ITALY |
San Gallicano Dermatological Institute Italy | ITALY |
Sullivan Nicolaides Pathology | AUSTRALIA |
Translational Research Institute | UNITED STATES |
University Claude Bernard | FRANCE |
University of Adelaide | AUSTRALIA |
University of California | UNITED STATES |
University of Copenhagen | DENMARK |
University of Groningen | NETHERLANDS |
University of Leeds | UNITED KINGDOM |
University of Manchester | UNITED KINGDOM |
University of Melbourne | AUSTRALIA |
University of Modena and Reggio Emilia | ITALY |
University of New South Wales | AUSTRALIA |
University of Queensland | AUSTRALIA |
University of South Australia | AUSTRALIA |
University of Sydney | AUSTRALIA |
University of Technology Sydney | AUSTRALIA |
University of Tsukuba | JAPAN |
University of Utah | UNITED STATES |
Veracity Clinical Research | AUSTRALIA |
Women's and Children's Hospital | AUSTRALIA |
Yale University | UNITED STATES |
External engagement & recognition
Engagement/recognition | Year |
---|---|
Career Development Fellow, Level IINational Health and Medical Research Council (NHMRC) |
2020 |
Career Development Fellow, Level IINational Health and Medical Research Council (NHMRC) |
2019 |
Career Development Fellow, Level IINational Health and Medical Research Council (NHMRC) |
2018 |
Career Development Fellow, Level IINational Health and Medical Research Council (NHMRC) |
2017 |
Career Development Fellow, Level IINational Health and Medical Research Council (NHMRC) |
2016 |
Naevus Research Funding $2,496,835 (5 years)National Health and Medical Research Council (NHMRC) Centre of Research Excellence |
2016 |
Inaugural Translational Research Institute Innovation AwardTranslational Research Institute |
2014 |
Innovation AwardInaugural Translational Research Institute |
2014 |
Invited SpeakerAnnual Australasian Wound and Tissue Repair Society Meeting, Gold Coast |
2014 |
Invited SpeakerAnnual Scientific Meeting FIP/Drug Delivery Australia, Melbourne |
2014 |
Invited SpeakerAnnual Scientific Meeting International Skin Imaging Collaboration, USA |
2014 |
Invited Speaker6th Joint Australia-New Zealand Chapters of the Controlled Release Society Workshop, Brisbane |
2013 |
Invited SpeakerAustralasian Society for Dermatology Research, Sydney |
2013 |
Invited SpeakerGlobal Investigative Dermatology Showcase, British Society of Dermatology, Edinburgh, United Kingdom |
2013 |
Invited SpeakerDrug Delivery Australia Annual Scientific Meeting, Sydney |
2013 |
Invited SpeakerDrug Discovery and Therapy World Congress in Boston, USA |
2013 |
Invited SpeakerJoint Meeting of the ICG/IDS/ISDIS, Miami, USA |
2013 |
Post-Doc (APR) Early Career Researcher best presentation awardAustralasian Society for Dermatology Research, Sydney |
2013 |
Invited SpeakerAmerican Academy of Dermatology Annual Scientific Meeting, San Diego, California |
2012 |
Invited SpeakerAustralasian Society for Dermatology Research Annual Scientific Meeting, Sydney |
2012 |
Invited SpeakerDrug Delivery Australia Annual Scientific Meeting, Melbourne |
2012 |
Invited SpeakerNanodermatology Society Annual Scientific Meeting, San Diego, USA |
2012 |
Invited SpeakerAustralasian Society for Dermatology Research Annual Scientific Meeting, Perth |
2011 |
Finalist, Eureka Prize for Excellence in Research by an Interdisciplinary TeamAustralian Research Council (ARC) |
2010 |
Highly Commended Open competitionUniversity of Queensland Trailblazer innovation and invention competition |
2010 |
Invited Speaker8th International Conference and Workshop on Biological Barriers, Saarbrucken, Germany |
2010 |
Teaching & student supervision
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
Molecular diagnosis for point-of-care skin cancer testing | Current |
The link of environmental chemicals in the pathogenesis and in the increasing incidence of prostate cancer in Australia | Current |